Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Rheumatology

Standard of Care Treatments and Medications

At a Glance

Hydroxychloroquine is the foundational standard of care treatment for lupus, proven to reduce flares and prevent organ damage. Treatment also focuses on a steroid-sparing strategy to keep prednisone doses low, using immunosuppressants or targeted biologics to manage severe disease activity.

Managing lupus is often compared to a “balancing act.” The goal is to keep your overactive immune system in check while minimizing the side effects of the very drugs that help you. Your care team follows a standard of care—a set of evidence-based guidelines designed to provide the best possible outcome for your specific case [1][2].

The Anchor: Hydroxychloroquine (HCQ)

Regardless of your symptoms, Hydroxychloroquine (HCQ)—brand name Plaquenil—is considered the “anchor” or foundational therapy for nearly every lupus patient [2].

  • Why it’s vital: HCQ is the only medication proven to reduce flares, prevent long-term organ damage, and even improve survival in lupus patients [3].
  • Eye Toxicity Risk: While very effective, HCQ can rarely cause irreversible damage to the retina (the back of the eye) [4]. This risk is related to the cumulative dose over many years. To stay safe, you must have a baseline eye exam when you start the drug. After that, annual screenings typically begin after five years of use, though your doctor may recommend them sooner if you are at higher risk [4].

The Steroid-Sparing Goal

Glucocorticoids (like Prednisone) are powerful anti-inflammatories that act like a “fire extinguisher” to put out an active lupus flare. However, long-term use of high doses causes permanent damage, including bone thinning (osteoporosis), cataracts, and weight gain.

  • The Target: Modern treatment focuses on a steroid-sparing strategy. The goal is to taper your Prednisone dose to 5 mg per day or less as soon as possible to prevent these long-term complications [5][6].

Scaling Treatment: The “Lupus Ladder”

Treatment is not “one size fits all.” It scales up based on the severity of your symptoms and which organs are involved:

  1. Mild Disease (Skin, joints, fatigue): Usually managed with HCQ and low-dose steroids as needed.
  2. Moderate Disease (Persistent inflammation): Your doctor may add an immunosuppressant like Mycophenolate Mofetil (MMF) or Azathioprine to help lower your steroid dose [7][6].
  3. Severe Disease (Kidney or brain involvement): This requires “induction therapy” to stop the attack quickly. This often involves high-dose steroids and potent drugs like Cyclophosphamide, followed by long-term maintenance [7][8].
  4. Targeted Biologics: If standard drugs aren’t enough, your doctor may prescribe “biologics”—highly targeted therapies like Belimumab (which blocks B-cells) or Anifrolumab (which blocks Interferon) [9][10].

Family Planning and Pregnancy Safety

Since lupus predominantly affects women of childbearing age, family planning is a critical conversation. Some of the most potent immunosuppressants used for severe lupus—specifically Mycophenolate Mofetil (MMF) and Cyclophosphamide—are highly teratogenic, meaning they cause severe birth defects [11][12].

  • Strict Contraception: If you are taking these medications, you must use highly effective, strict contraception.
  • Planning Ahead: You can still have a safe and successful pregnancy with lupus, but it requires careful planning. Always consult your rheumatologist and an obstetrician before trying to conceive, ideally waiting until your lupus has been in remission for at least six months. They will safely transition you to pregnancy-compatible medications.

Summary of Key Medications

Drug Category Common Names Primary Role
Antimalarials Hydroxychloroquine Foundation; prevents flares and organ damage [2].
Steroids Prednisone Fast relief for active flares; goal is to use the lowest dose [5].
Immunosuppressants MMF, Cyclophosphamide “Heavy hitters” used for organ involvement or to lower steroid use [7].
Biologics Belimumab, Anifrolumab New, targeted treatments that block specific parts of the immune system [9][10].

Common questions in this guide

Why is hydroxychloroquine prescribed for almost all lupus patients?
Hydroxychloroquine is considered the foundational therapy for lupus. It is the only medication proven to reduce disease flares, prevent long-term organ damage, and improve overall survival.
What is the steroid-sparing goal in lupus treatment?
The goal is to taper your daily prednisone dose to 5 mg or less as quickly as possible. This helps prevent permanent side effects of long-term steroid use, such as bone thinning, cataracts, and weight gain.
Do I need regular eye exams if I take hydroxychloroquine?
Yes, hydroxychloroquine can rarely cause irreversible damage to the retina over time. You should have a baseline eye exam when starting the drug and regular follow-up screenings to monitor for any changes.
Can I safely get pregnant while taking lupus medications?
You can have a safe pregnancy with lupus, but it requires careful planning with your rheumatologist and obstetrician. Some severe lupus medications cause serious birth defects and must be stopped well before conceiving.
What are biologic treatments for lupus?
Biologics like belimumab and anifrolumab are highly targeted therapies that block specific parts of the immune system. They are typically prescribed if standard lupus medications and immunosuppressants are not effectively controlling your symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my Hydroxychloroquine dose based on my actual body weight to minimize the risk of eye toxicity?
  2. 2.When should I schedule my next retinal exam, and what specific tests (like a visual field or OCT) will they perform?
  3. 3.What is my target date for tapering my Prednisone dose to below 5 mg/day?
  4. 4.If we are moving to an immunosuppressant like MMF, how will we monitor for side effects like low white blood cell counts?
  5. 5.Based on my current organ involvement, where am I on the 'treatment ladder,' and what would trigger a move to a biologic like Belimumab or Anifrolumab?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Multidisciplinary care in patients with systemic lupus erythematosus: a randomized controlled trial in China.

    Zhang L, Geng S, Qian L, et al.

    International journal of clinical pharmacy 2019; (41(5)):1247-1255 doi:10.1007/s11096-019-00870-y.

    PMID: 31240553
  2. 2

    Belimumab for the treatment of pediatric patients with lupus nephritis.

    Stohl W, Kwok A

    Expert opinion on biological therapy 2023; (23(3)):243-251 doi:10.1080/14712598.2023.2178297.

    PMID: 36750049
  3. 3

    Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?

    Cunha C, Alexander S, Ashby D, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(9)):1604-1610 doi:10.1093/ndt/gfx318.

    PMID: 29186572
  4. 4

    An Uncommon Correlation of Rheumatoid Arthritis and Lupus Nephritis: A Case Report on the Unusual Progression of Lupus Nephritis.

    Lam LC, Yadav VD, Mihal VJ

    Cureus 2022; (14(8)):e27620 doi:10.7759/cureus.27620.

    PMID: 36134049
  5. 5

    Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study.

    Pappa M, Kosmetatou M, Elezoglou A, et al.

    Mediterranean journal of rheumatology 2022; (33(2)):263-267 doi:10.31138/mjr.33.2.263.

    PMID: 36128201
  6. 6

    2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.

    Fanouriakis A, Kostopoulou M, Cheema K, et al.

    Annals of the rheumatic diseases 2020; (79(6)):713-723 doi:10.1136/annrheumdis-2020-216924.

    PMID: 32220834
  7. 7

    Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.

    Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, et al.

    The Journal of rheumatology 2015; (42(11)):2082-91 doi:10.3899/jrheum.150395.

    PMID: 26373566
  8. 8

    A clinico-pathological study of lupus nephritis based on the International Society of Nephrology-Renal Pathology Society 2003 classification system.

    Satish S, Deka P, Shetty MS

    Journal of laboratory physicians 2017; (9(3)):149-155 doi:10.4103/JLP.JLP_44_16.

    PMID: 28706383
  9. 9

    Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study.

    Nakai T, Fukui S, Sawada H, et al.

    Lupus 2023; (32(13)):1518-1527 doi:10.1177/09612033231208845.

    PMID: 37858981
  10. 10

    Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico.

    González-Meléndez A, Báez-Negrón L, Ríos-Rivera R, et al.

    Lupus 2023; (32(4)):571-579 doi:10.1177/09612033231151898.

    PMID: 36639887
  11. 11

    Neuropsychiatric Systemic Lupus Erythematosus with Cerebral Vasculitis and Lupus Nephritis Successfully Treated with High-dose Glucocorticoids and Mycophenolate Mofetil.

    Tanaka S, Kawaguchi T, Kudo R, et al.

    Internal medicine (Tokyo, Japan) 2022; (61(20)):3131-3135 doi:10.2169/internalmedicine.9123-21.

    PMID: 35283391
  12. 12

    Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil.

    Higashioka K, Yoshida K, Oryoji K, et al.

    Internal medicine (Tokyo, Japan) 2015; (54(17)):2255-9 doi:10.2169/internalmedicine.54.4582.

    PMID: 26328657

This page explains standard lupus treatments and medications for educational purposes. Always consult your rheumatologist before starting, stopping, or changing any of your medications.

Get notified when new evidence is published on Systemic lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.